Reina J
Unidad de Virología, Servicio de Microbiología, Hospital Universitario Son Espases, Palma de Mallorca, Baleares, España.
Vacunas. 2012 Apr-Jun;13(2):64-68. doi: 10.1016/S1576-9887(12)70039-0. Epub 2012 Nov 23.
Virus-like particles (VLPs) are multimeric protein complexes mimicking the organization of native viruses but lack the viral genome. VLPs therefore constitute a safe and effective approach for the induction of neutralizing antibodies to surface proteins. Influenza VLPs have recently been developed as a new generation of non-egg based cell culture-derived vaccine candidates against influenza infection. FluBock, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to classical inactivated influenza vaccines. The highly purified protein vaccine, administered with a three-fold higher antigen content (135 μg), is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses.
病毒样颗粒(VLPs)是模仿天然病毒结构的多聚体蛋白复合物,但缺乏病毒基因组。因此,VLPs是诱导针对表面蛋白的中和抗体的一种安全有效的方法。流感病毒样颗粒最近已被开发为新一代基于细胞培养而非鸡蛋来源的抗流感感染候选疫苗。FluBock是一种使用杆状病毒表达系统在昆虫细胞培养中生产的重组三价血凝素(rHA)疫苗,是传统灭活流感疫苗的一种有吸引力的替代品。这种高度纯化的蛋白疫苗,其抗原含量高三倍(135μg),耐受性良好,能产生更强的免疫原性、持久的免疫反应,并能提供针对流感病毒变异株的交叉保护。